{"id":1167,"date":"2016-09-02T17:46:38","date_gmt":"2016-09-02T12:16:38","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1167"},"modified":"2021-07-24T12:56:31","modified_gmt":"2021-07-24T07:26:31","slug":"notizia-4","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-4","title":{"rendered":"Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f8bc6862f2d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f8bc6862f2d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-4\/#Game_changing_agent_Opdivo_on_a_threshold_to_change_standard_of_care_in_squamous_cell_carcinoma_of_the_head_and_neck_SCCHN\" >Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-4\/#Rucaparib_receives_Priority_review_designation_from_FDA_for_advanced_BRCA%E2%80%93mutated_ovarian_cancer\" >Rucaparib receives Priority review designation from FDA for advanced\u00a0BRCA\u2013mutated ovarian cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-4\/#Sunovion_Pharmaceuticals_set_to_buy_Canadas_Cynapsus_Therapeutics_for_about_624_million\" >Sunovion Pharmaceuticals set to buy Canada&#8217;s Cynapsus Therapeutics for about $624 million.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-4\/#Pharma_company_Insys_marketed_opioid_drug_at_high-volume_prescribers_%E2%80%93_lawsuit\" >Pharma company Insys marketed opioid drug at high-volume prescribers \u2013 lawsuit<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Game_changing_agent_Opdivo_on_a_threshold_to_change_standard_of_care_in_squamous_cell_carcinoma_of_the_head_and_neck_SCCHN\"><\/span>Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, Nivolumab (Opdivo) is ready to become the new standard-of-care option for all platinum-refractory patients with head and neck cancer, as per the recent findings. The PD-L1 inhibitor has received a priority review designation by the FDA in July 2016 based on the CheckMate-141 study, as presented in the ASCO 2016 Annual Meeting.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Rucaparib_receives_Priority_review_designation_from_FDA_for_advanced_BRCA%E2%80%93mutated_ovarian_cancer\"><\/span>Rucaparib receives Priority review designation from FDA for advanced\u00a0<em>BRCA<\/em>\u2013mutated ovarian cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">FDA granted priority review status to rucaparib of Clovis Oncology for the patients who have undergone 2 or more platinum based therapy for treatment of <em>BRCA-<\/em>mutated ovarian cancer. FDA is also set to make a decision regarding the acceptance of NDA for this molecule, by going through the ARIEL clinical program conducted in females with advanced ovarian cancer. Treating women with germline or somatic <em>BRCA<\/em> mutations after 2 platinum based therapies with rucaparib has indicated a great step forward in its treatment.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Sunovion_Pharmaceuticals_set_to_buy_Canadas_Cynapsus_Therapeutics_for_about_624_million\"><\/span>Sunovion Pharmaceuticals set to buy Canada&#8217;s Cynapsus Therapeutics for about $624 million.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Sunovion Pharmaceuticals Inc, a unit of Japan&#8217;s Dainippon Sumitomo Pharma Co Ltd, has planned to buy Canada\u2019s Cynapsus Therapeutics, according to recent reports. Sunovion will acquire Cynapsus\u2019 drug candidate, APL-130277, which is currently in its phase three clinical trial stage. It is designed to be an easy to administer, sublingual thin film of apomorphine to manage OFF episodes associated with Parkinson\u2019s disease.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Pharma_company_Insys_marketed_opioid_drug_at_high-volume_prescribers_%E2%80%93_lawsuit\"><\/span>Pharma company Insys marketed opioid drug at high-volume prescribers \u2013 lawsuit<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Insys Therapeutics Inc. has been accused of deceptive marketing practices involving a cancer drug and using &#8220;sham&#8221; speaking events to target doctors known to frequently prescribe opioid drugs, in a lawsuit filed by State of Illinois. The lawsuit filed alleges that Insys did not market its drug Subsys, designed and approved to manage cancer pain, to oncologists but rather to doctors with a reputation for high-volume approval of opioid prescriptions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, Nivolumab (Opdivo) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1305,698,17300,704,17302,431,444,17304,17303,17117,17301],"industry":[17225],"therapeutic_areas":[17228,17234],"class_list":["post-1167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-brca","tag-carcinoma","tag-cynapsus-therapeutics","tag-fda","tag-insys","tag-opdivo","tag-ovarian-cancer","tag-rucaparib","tag-scchn","tag-squamous-cell-carcinoma","tag-sunovion-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys<\/title>\n<meta name=\"description\" content=\"Nivolumab (Opdivo) is ready to become the new standard-of-care option for all platinum-refractory patients with head and neck cancer...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-4\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys\" \/>\n<meta property=\"og:description\" content=\"Nivolumab (Opdivo) is ready to become the new standard-of-care option for all platinum-refractory patients with head and neck cancer...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-4\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-02T12:16:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"301\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys","description":"Nivolumab (Opdivo) is ready to become the new standard-of-care option for all platinum-refractory patients with head and neck cancer...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-4","og_locale":"en_US","og_type":"article","og_title":"Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys","og_description":"Nivolumab (Opdivo) is ready to become the new standard-of-care option for all platinum-refractory patients with head and neck cancer...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-4","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-09-02T12:16:38+00:00","article_modified_time":"2021-07-24T07:26:31+00:00","og_image":[{"width":960,"height":301,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-4","url":"https:\/\/www.delveinsight.com\/blog\/notizia-4","name":"Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-4#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-4#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","datePublished":"2016-09-02T12:16:38+00:00","dateModified":"2021-07-24T07:26:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Nivolumab (Opdivo) is ready to become the new standard-of-care option for all platinum-refractory patients with head and neck cancer...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-4"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-4#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","width":960,"height":301},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720-300x94.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BRCA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cynapsus Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Insys<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Opdivo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ovarian Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rucaparib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SCCHN<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Squamous Cell Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sunovion Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BRCA<\/span>","<span class=\"advgb-post-tax-term\">carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Cynapsus Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Insys<\/span>","<span class=\"advgb-post-tax-term\">Opdivo<\/span>","<span class=\"advgb-post-tax-term\">Ovarian Cancer<\/span>","<span class=\"advgb-post-tax-term\">Rucaparib<\/span>","<span class=\"advgb-post-tax-term\">SCCHN<\/span>","<span class=\"advgb-post-tax-term\">Squamous Cell Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Sunovion Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 2, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 2, 2016 5:46 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1167"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1167\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1173"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1167"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1167"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}